Fatty Liver Disease in People With Type 2 Diabetes in China
Studies how often fatty liver disease occurs in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Key facts
- Where
- Nanjing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes in Jiangsu Province, China, who have had a liver fat measurement (UAP) taken with an iLivTouch device. It studies how common fatty liver disease linked to metabolism is.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Type 2 diabetes, diagnosed according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes.
- Biomarker or test result
- Liver fat (UAP) measured with iLivTouch.
Main reasons for not taking part
- Other types of diabetes
- Unable to attend regular follow-up
Read by machine on 12 November 2026.
Where in China
- Zhongda Hospital, Medical School, Southeast UniversityNanjing, ChinaContact: Ling Li, ProfessorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Wuxi Hisky Medical Technology Co Ltd
- Trial code
- NCT05597709
- Record updated
- 28 October 2022
- Original description
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.Read full original descriptionShow less
Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.
Inclusion: Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes; UAP were measured based on iLivTouch; Willing to attend this study and able to provide the written informed consent.
Exclusion: Other types of diabetes; Patients unable to receive regular follow-up.